MOTS-c (mitochondrial-derived peptide)

Overview

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a short bioactive peptide of 16 amino acids belonging to the family of mitochondrial-derived peptides (MDPs). Unlike the vast majority of cellular proteins encoded by the nuclear genome, MOTS-c is translated from a small open reading frame embedded within the 12S ribosomal RNA gene (MT-RNR1) of mitochondrial DNA. The peptide is positioned as an intracellular and endocrine regulator of metabolic homeostasis that links mitochondrial energy-state signals to nuclear transcriptional adaptations ^[1][5]. This material is regarded strictly as a laboratory research reagent (RUO); the chemistry, structure and published scientific record are described below, without any guidance for use in humans.

Discovery and background

MOTS-c was identified in 2015 by the group led by Pinchas Cohen through in silico analysis of small potentially coding frames within the mitochondrial genome, followed by biochemical confirmation of peptide translation ^[1]. Its discovery extended the concept initiated by humanin (the first described MDP) that mitochondria are not solely energy organelles but also a source of signaling polypeptides. The finding reshaped the view of the "silent" regions of rRNA genes: MT-RNR1 proved to carry additional genetic information read in an alternative frame. Soon after the discovery, a polymorphism common in Japanese populations within the region encoding MOTS-c (a variant causing a K228Q substitution in the peptide, linked to haplogroup D) was shown to associate with longevity in men, providing a genetic context for the peptide's physiological role ^[2].

Structure and physicochemistry

The mature human MOTS-c sequence is MRWQEMGYIFYPRKLR (16 residues), with an average molecular mass of approximately 2174.6 g/mol. The molecule is enriched in aromatic (Trp, two Tyr, Phe) and basic (three Arg, Lys) residues, conferring a pronounced net positive charge at physiological pH and a strong capacity to interact with nucleic acids and negatively charged surfaces. MOTS-c contains no cysteine residues and therefore forms no intra- or intermolecular disulfide bridges. In solution the peptide is largely disordered, yet the basic cluster at its C-terminus is consistent with a nuclear-localization function that is activated under appropriate conditions. Owing to its compact size and lack of a deep hydrophobic core, MOTS-c is readily soluble in aqueous buffers, although the aromatic residues give it a tendency to aggregate at high concentrations ^[3].

Molecular mechanism

The central node of MOTS-c action is considered to be the metabolic sensor AMP-activated protein kinase (AMPK). Early studies showed that the peptide affects the folate cycle and one-carbon metabolism, lowering the levels of intermediates (notably 5-methyltetrahydrofolate), which leads to accumulation of AICAR (an endogenous AMPK activator) and consequently to activation of the AMPK axis ^[1][3]. Activated AMPK switches the cell from anabolic to catabolic programs: glucose uptake, fatty-acid oxidation and mitochondrial biogenesis are enhanced. MOTS-c thus functions as a retrograde "mitochondria → cytosol/nucleus" signal that informs the cell of its energy-balance state ^[7].

Signaling and nuclear translocation

A fundamentally important discovery is that, under metabolic stress (fasting, glucose deprivation, oxidative stress), MOTS-c relocates from the cytoplasm to the nucleus ^[4]. Nuclear translocation is AMPK-dependent and involves interaction of the peptide with stress-response transcription factors, in particular the NRF2/NFE2L2 family and ARE-dependent promoters (antioxidant response element). In the nucleus MOTS-c modulates the expression of antioxidant-defense and metabolic-adaptation genes, acting as a regulator of the adaptive nuclear response to cellular stress ^[4][5]. The ability of a small mitochondrially encoded peptide to directly influence nuclear transcription conceptually sets MOTS-c apart from classical hormones and makes it an example of mitochondrial-to-nuclear communication.

Preclinical research findings

In preclinical models (cell cultures, rodents) MOTS-c displayed a broad spectrum of metabolic effects. In mice on a high-calorie diet, administration of the peptide in experimental work was associated with reduced insulin resistance, improved glucose tolerance and decreased adipose accumulation ^[1]. In skeletal muscle MOTS-c enhanced insulin-independent glucose uptake through AMPK-dependent mechanisms. Aging studies showed that MOTS-c levels and activity decline with age, and administration of the peptide in models improved measures of physical function and muscle homeostasis in aged animals ^[8]. Separate research directions addressed protection from inflammation, hepatic metabolic dysfunction and bone metabolism, although these data remain largely at the level of cell and animal models ^[10].

Clinical / human research (as literature)

Direct interventional clinical trials of MOTS-c are, at the time of this review, limited; available data are predominantly observational. In humans MOTS-c is detectable in plasma, and its circulating level is modulated by physical activity: acute and training protocols were associated with changes in peptide concentration in skeletal muscle and blood, consistent with the concept of MOTS-c as an exercise-induced "myokine-like" mediator ^[8]. In patients with type 2 diabetes, reduced levels of mitochondrial-derived peptides, including MOTS-c, have been described relative to controls, positioning the peptide as a potential biomarker of metabolic state ^[6]. Genetic associations of longevity with variants of the coding region further support the peptide's physiological relevance in humans ^[2].

Pharmacokinetics and metabolism

As a short, unprotected peptide, MOTS-c in circulation undergoes rapid proteolysis by plasma and tissue exo- and endopeptidases, resulting in a short biological half-life (on the order of minutes), although precise human parameters are not strictly established. The peptide is filtered by the kidneys owing to its small size. Endogenously, MOTS-c levels are regulated by the cell's metabolic state and mitochondrial function rather than by mtDNA expression alone ^[7]. The basic C-terminal residues (Arg/Lys) make the peptide a substrate for trypsin-like proteases, an important factor when planning analytics and stability experiments ^[3].

Related compounds and analogues

MOTS-c belongs to the expanding MDP family, which includes humanin (the first described MDP, encoded in 16S rRNA/MT-RNR2) and a series of small humanin-like peptides SHLP1–6 ^[9]. Unlike humanin, which acts mainly cytoprotectively and anti-apoptotically through cell-surface receptors, MOTS-c is more associated with metabolic regulation and direct nuclear action ^[3][9]. Synthetic analogues bearing modifications to increase proteolytic stability (residue substitutions, cyclization, conjugation) aimed at extending duration of action in experimental systems are also under study ^[10]. Comparative analysis of MDPs remains an active field in mitochondrial-nuclear signaling research.

Analytical characterization

The identity and purity of research-grade MOTS-c preparations are typically confirmed by reverse-phase HPLC (RP-HPLC) with detection at 214–280 nm (using aromatic Trp/Tyr absorbance) and mass spectrometry (ESI-MS or MALDI-TOF), where the expected monoisotopic/average mass should match ≈2174.6 Da. Precise sequence identification is possible via tandem MS (MS/MS) fragmentation and Edman sequencing. For quantification in biological samples, immunoassays (ELISA) and targeted LC-MS/MS are used. Key reagent-quality criteria are chromatographic purity (typically ≥95–98%), absence of deletion/truncation forms, and control of counter-ion content (e.g., acetate or trifluoroacetate) and residual water ^[3].

Handling, reconstitution chemistry and storage

Lyophilized MOTS-c is stored at −20 °C or below, in sealed containers protected from moisture and light; under these conditions the dry peptide is stable for extended periods. Reconstitution typically uses sterile water or aqueous buffers; if dissolution of the basic/aromatic peptide is difficult, brief use of dilute solutions with a small amount of an appropriate co-solvent is possible (within limits that do not compromise downstream analyses). After reconstitution, solutions should be aliquoted and stored frozen, avoiding repeated freeze-thaw cycles that promote aggregation and proteolytic degradation. All manipulations are performed in a laboratory context following good reagent-handling practice. These recommendations concern reagent stability and are not use directions.

Research applications and model systems

MOTS-c is used as a tool to study mitochondrial-nuclear communication, retrograde signaling, the role of AMPK in metabolic adaptation, and aging biology. Typical model systems include myoblast and adipocyte cultures, primary hepatocytes, cell lines for nuclear-translocation assays (fluorescently labeled peptide, confocal microscopy), and rodent models to assess metabolic and age-dependent phenotypes ^[4][8]. The peptide also serves as a reference ligand in MDP-family studies and in the development of analytical detection methods ^[7][10]. Current directions include elucidating the precise molecular targets in the nucleus, the mechanisms of secretion and transport, and the interplay of MOTS-c with other stress-response pathways ^[5][10].